62 related articles for article (PubMed ID: 1602137)
1. Identification and characterization of the effector region within human C5a responsible for stimulation of IL-6 synthesis.
Morgan EL; Sanderson S; Scholz W; Noonan DJ; Weigle WO; Hugli TE
J Immunol; 1992 Jun; 148(12):3937-42. PubMed ID: 1602137
[TBL] [Abstract][Full Text] [Related]
2. Biologic activity of synthetic analogues of C5a anaphylatoxin.
Ember JA; Sanderson SD; Taylor SM; Kawahara M; Hugli TE
J Immunol; 1992 May; 148(10):3165-73. PubMed ID: 1578141
[TBL] [Abstract][Full Text] [Related]
3. Anti-C5a receptor antibodies. Characterization of neutralizing antibodies specific for a peptide, C5aR-(9-29), derived from the predicted amino-terminal sequence of the human C5a receptor.
Morgan EL; Ember JA; Sanderson SD; Scholz W; Buchner R; Ye RD; Hugli TE
J Immunol; 1993 Jul; 151(1):377-88. PubMed ID: 8326131
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human C5a induces transcription but not translation of interleukin 1 beta mRNA in human monocytes.
Geiger T; Rordorf C; Galakatos N; Seligmann B; Henn R; Lazdins J; Erard F; Vosbeck K
Lymphokine Cytokine Res; 1992 Feb; 11(1):55-63. PubMed ID: 1576247
[TBL] [Abstract][Full Text] [Related]
5. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
6. The role of C5a in interleukin-6 production induced by lipopolysaccharide or interleukin-1.
Montz H; Koch KC; Zierz R; Götze O
Immunology; 1991 Nov; 74(3):373-9. PubMed ID: 1769685
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the C-terminal C5a effector site with short synthetic C5a analog peptides.
Köhl J; Lübbers B; Klos A; Bautsch W; Casaretto M
Eur J Immunol; 1993 Mar; 23(3):646-52. PubMed ID: 8383599
[TBL] [Abstract][Full Text] [Related]
8. The pharmacophore of the human C5a anaphylatoxin.
Toth MJ; Huwyler L; Boyar WC; Braunwalder AF; Yarwood D; Hadala J; Haston WO; Sills MA; Seligmann B; Galakatos N
Protein Sci; 1994 Aug; 3(8):1159-68. PubMed ID: 7987211
[TBL] [Abstract][Full Text] [Related]
9. Expression of functional receptors for human C5a anaphylatoxin (CD88) on the human hepatocellular carcinoma cell line HepG2. Stimulation of acute-phase protein-specific mRNA and protein synthesis by human C5a anaphylatoxin.
Buchner RR; Hugli TE; Ember JA; Morgan EL
J Immunol; 1995 Jul; 155(1):308-15. PubMed ID: 7541417
[TBL] [Abstract][Full Text] [Related]
10. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1 upregulates anaphylatoxin receptors on mononuclear cells.
Takabayashi T; Shimizu S; Clark BD; Beinborn M; Burke JF; Gelfand JA
Surgery; 2004 May; 135(5):544-54. PubMed ID: 15118592
[TBL] [Abstract][Full Text] [Related]
12. Antagonistic peptides against human anaphylatoxin C5a.
Kaneko Y; Okada N; Baranyi L; Azuma T; Okada H
Immunology; 1995 Sep; 86(1):149-54. PubMed ID: 7590876
[TBL] [Abstract][Full Text] [Related]
13. Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides.
Baranyi L; Campbell W; Okada H
J Immunol; 1996 Nov; 157(10):4591-601. PubMed ID: 8906838
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
15. Conformationally biased analogs of human C5a mediate changes in vascular permeability.
Kawatsu R; Sanderson SD; Blanco I; Kendall N; Finch AM; Taylor SM; Colcher D
J Pharmacol Exp Ther; 1996 Jul; 278(1):432-40. PubMed ID: 8764379
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin.
Ni F; Carpenter KA; Ripoll DR; Sanderson SD; Hugli TE
Biopolymers; 1996 Jan; 38(1):31-41. PubMed ID: 8679942
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic therapy induces expression of interleukin 6 by activation of AP-1 but not NF-kappa B DNA binding.
Kick G; Messer G; Goetz A; Plewig G; Kind P
Cancer Res; 1995 Jun; 55(11):2373-9. PubMed ID: 7757989
[TBL] [Abstract][Full Text] [Related]
18. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
19. IL-6 and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming effect of IFN-gamma.
Sanceau J; Wijdenes J; Revel M; Wietzerbin J
J Immunol; 1991 Oct; 147(8):2630-7. PubMed ID: 1918983
[TBL] [Abstract][Full Text] [Related]
20. Effects of site-specific mutations on biologic activities of recombinant human IL-6.
Snouwaert JN; Kariya K; Fowlkes DM
J Immunol; 1991 Jan; 146(2):585-91. PubMed ID: 1987278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
